Buradasınız

Anasayfa » Content

TİP 2 DİYABETLİ HASTALARDA DİYET, SÜLFONİLÜRE GRUBU ORAL ANTİDİYABETİK İLAÇLAR VE İNSÜLİN TEDAVİSİNİN KAN ŞEKERİ ÜZERİNDEKİ ETKİLERİ

Effects of diet, sulphonylurea group of oral antidiabetic drugs and insulin treatment on blood glucose levels in patients with Type 2 diabetes mell tus

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 1999

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
In this randomized prospective study, we investigated the effects of diet, gliclazide, gliclazide and acarbose and insulin on blood glucose levels of Type 2 diabetic patients. Sixty-four patients, 30 males (12 obese and 18 non-obese) and 34 females (20 obese and 14 non-obese), aged 50.83"6.88 years (range 36-66) with a fasting blood glucose level of 140 to 270 mg/dL were included. Patients were divided into two groups (obese and nonobese) before random zat on and both groups were divided into four subgroups consisting of diet, gliclazide, gliclazide and acarbose and insulin. Patents were re-evaluated at 14 and 28 weeks. Prior to study, mean (" SD) fasting blood glucose level was 203.43 (27.05) mg/dl, HbAc was 8.38% (0.71), body weight was 76.78 (7.25) kg, fasting plasma insulin was 33.85 (7.49) g/ml, and C-peptide level was 4.08 (0.76) ng/ml. After seven months of treatment, mean (" SD) decrease in fasting blood glucose level was 23.14 (10.62) mg/dl and 0.59% (0.08) in HbA1c. There was an increase of 1.69 (0.05) kg in body weight, 1.97 (0,44) jjg/ml in fasting plasma insulin, and 4.08 (0.76) ng/ml in C-peptide levels. In conclusion, we observed that gliclazide, gliclazide and acarbose, and insulin treatments were more effective than diet alone. However, no significant difference was observed between treatment groups in terms of improved metabolic state.
Bookmark/Search this post with
Abstract (Original Language): 
Bu randomize prospektif çalışmada, tip 2 diyabetli hastalarda diyet, gliklazid, gliklazid Dr. Haluk ŞAVLI - ile akarboz ve insülin tedavilerinin kan şekeri üzerine etkileri araştırıldı. Açlık kan Dr. Servet SERBEST - şekeri 140 ile 270 mg/dL arasında değişen ve ortalama yaşlar 50.83± 6.88 (36-66) Dı-. Alper SEVİI\IÇ -# yl olan 30 erkek (12 obez ve 18 nonobez) ve 34 kadın (20 obez ve 14 nonobez) Dr. Süleyman BUYUKBERBER- toplam 64 hasta çalışmaya alındı. Hastalar randomize edilmeden önce iki gruba ayrıldı (obez ve nonobez) ve her iki grup kendi içinde diyet, gliklazid, gliklazid ile akarboz ve nsül n tedav ler nden oluşan 4 alt gruba ayrıldı. Hastalar 14. ve 28. haftalarda tekrar değerlendirildi. Tedavi öncesinde, ortalama (±SD) açlık kan şekeri 203.43 (27.05) mg/dl, HbAc %8.38 (0.71), vücut ağırlığı 76.78 (7.25) kg, açlık plazma insül ini 33.85 (7.49) g/ml ve C-peptid 4.08 (0.76) ng/ml idi. Yedi aylık tedavi sonrasında, ortalama (±SD) açlık kan şekerinde 23.14 (10.62) mg/dl ve HbAc de %0.59 (0.08) düşme görüldü. Açlık plazma insülinde 1.97 (0,44) ytg/ml'lik, C-peptid seviyesinde 2.03 (0.07) ng/ml'lik ve vücut ağırlığında 1.69 (0.05) kglık artış saptandı. Sonuç olarak, hastalarda gliklazid, gliklazid ile akarboz ve insülin tedavilerin, sadece diyet tedavisinden daha etkili olduğu görüldü. Bununla birlikte, tedav grupları arasında metabol k durumu düzeltme açısından öneml b r fark saptanmadı.
FULL TEXT (PDF): 
PDF icon arastirmax-tip-2-diyabetli-hastalarda-diyet-sulfonilure-grubu-oral-antidiyabetik-ilaclar-insulin-tedavisinin-kan-sekeri-uzerindeki-etkileri.pdf
  • 2
118-124
  • Turkish

REFERENCES

References: 

1.
Öze
r E. D iyabet eğ it im i ve önem i. Aktüel Tıp Derg i si 1996;1(8):566-9.
2. Groop
LC
. Early metabol i c abnormal iti es i n NIDDM. D i abetes Rev 1995; 4:9-12.
3. Un ited Ki ngdom prospective d iabetes study (UKPDS) 13: relative effi cacy of randomly allocated d i et, sulphonylurea, insul i n, or metform in i n patients with newly d iagnosed non-insuli n dependent d iabetes followed for three years. BMJ 1995;310:83-8.
4.
Yılma
z C. Tip 2 Diabeti n medi kal tedavisi. Aktüel Tıp Derg isi 1996;1(8):560-5.
5. Thomas
HA
, Lean MEJ. D i et i n NIDDM. Pi ckup J, Wi ll iams G (eds), D i abetes, 2nd ed, Blackwell Sc i ence, Victori a, 1997;1: 37.1-15.
6. Un ited Ki ngdom prospective d iabetes study (UKPDS) V2I. Study desi gn, progress and performance. D iabetolog i a 1991;34:877-90.
7. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC. UKPDS 26:
Sulphonylurea fa i lure i n non-insul i n-dependent d i abet ic pati ents over six years. Un ited Kingdom prospective d i abetes study (UKPDS) Group. D i abet Med 1998;15(4):297-303.
8. Soonthornpun S, Rattarasarn C, Thampras t A, Leetanaporn K. Effect of acarbose i n treatment of type 2 d i abetes mell itus: a double-bl i nd, crossover, placebo-controlled tri al. J Med Assoc Tha i 1998; 81(3):195-
200.
9. Gudat U, Bungert S, Kemmer F, He i nemann L. The blood glucose loweri ng effects of exerc ise and gl i benclam ide i n pati ents with type 2 d i abetes mell itus. D i abet Med 1998;15(3):194-8.
10. Mult i -centre study: UK Prospective study of therap i es of maturity onset d i abetes. Effect of d iet, sulfonylurea, i nsul i n or b i guan i de therapy on fasti ng plasma glucose and body we i ght over one year. D i abetolog ia 1983;24:404.
11. L i gtenberg JJ, Venker CE, Slu iter WJ, Re itsma WD, Van Haeften TW. Effect of gl i benclam i de on i nsul in release at moderate and h i gh blood glucose levels i n normal man. Eur J Cl i n Invest 1997;27 (8):685-9.
12. Sakamoto N, Uno T. Oral hypoglycem ic agents. N i ppon Ri nsho
1997;55:94-8.
13. Johnson PS, Con iff RF, Hoogwerf BJ, et al. Effects of the carbohydrate i nh i b itor m i gl itol in sulfonylurea treated NIDDM pati ents. D i abetes Care 1994;17:20-9.
14.
Ertür
k E, İmamoğlu Ş. İnsül i n tedavi si prensi pleri. Galenos 1997;1:4-7.
15. Edelman SV. New oral anti d iabet i c agents for the prevent on and management of NIDDM. Int D iab Mon itor 1995;8(4):1-8.
16.
Aza
l Ö, Yönem A, Önde ME, Çorakçı A. İnsül ine bağımlı olmayan d i abetes mell ituslu hastalarda sülfon ilüre tedavi si ne akarboz ilavesi n in etki nl i ğ i. Türk D iabet Yıllığı 1997-1998;229-33.
17.
Düzçeke
r Ö, Sermez Y, Cankurtaran C. Alfa glukozidaz i nh ibitörü akarbozun ti p 2 d i abetes mell itus tedav is indeki etki nl i ğ i. Ulusal D iabet Kongres i. Kayser i, 1995:119.
18.
Da
ğ A. Örük G, Yıldırım Y. Ti p 2 d i abetes mell itusun tedavi si nde akarbozun etki nl i ğ i. Ulusal D i abet Kongres i. Kayser i ,1995:124.
19.
Ma
y C. Effi cacy and tolerab i l ity of stepwi se i ncreas ing dosage of acarbose i n pati ents with non i nsul i n dependent d i abetes mell itus treated with sulfonylureas. D i abetes Stoffwechsel 1995;4:3.
20. Con iff
RF
, Shapi ro JA, Seaton TB, et al. Multi center, placebo controlled tri al compari ng acarbose with placebo, tolbutam id, and tolbutam id-plus acarbose i n non insul i n dependent d iabetes mell itus. Am J Med 1995;98:443.
21.
Bayrakta
r M, Adalar N, Van Th i el DH. A compari son of acarbose versus metform i n as an adjunct therapy i n sulfonylurea treated NIDDM pati ents. D i abetes Care 1996;19:252.
22. Garci a RM, Muj ica V, Munoz S, Durruty P, Larenas G. Cl i n i cal experience with an alpha glucosi dase inh i b itor (acarbose) i n the treatment of non insul i n dependent diabetes. Multicenter study. Rev Med Ch i ll 1997;125(8):856-62.
23. Bi rkeland KI, Rishaug U, Hanssen KF, Vaaler S. NIDDM: a rapid progressive d isease. Results from a long-term, random ized, comparat ive study of i nsul i n or sulphonylurea treatment. Diabetolog ia 1996;39(12):1629-33.
24. Hoffmann J, Spengler M. Effi cacy of 24-week monotherapy with acarbose, metform i n, or placebo i n d i etary-treated NIDDM pat ients: the Essen-2 Study. Am J Med 1997;103(6):483-90.
25. Costa B, Pi nol C. Acarbose i n ambulatory treatment of non-insul i n-dependent d i abetes mell itus associ ated to i mm i nent sulfonylurea failure: a random i sed-multi centri c tri al in primary health-care. D i abetes and Acarbose Research Group. D i abetes Res Cl i n Pract 1997; 38(1):33-40.
26. S i m its P, B ijlstra PJ, Russel FG, Lutterman JA, Th i en T. Card iovascular effects of sulphonylurea derivatives. Diabetes Res Cl i n Pract 1996;31:55-9.
27. Rachman J, Payne JM, Levy JC, Barrow BA, Holman RR, Turner RC. Changes i n amyl i n and amyl i n-l i ke pepti de concentrat ions and p-cell funct i on i n response to sulfonylurea or i nsul i n therapy in NIDDM. D i abetes Care 1998; 21(5):810-5.
28. The D i abetes Control and Compl i cati ons Tri al Research Group. The effect of intensive treatment of d i abetes on the development and progression of long-term compl icat ions i n i nsul i n-dependent d iabetes mell itus. N Engl J Med 1993;329:977-86.
29. Jones DB, G i ll GV. Management of NIDDM. Pi ckup J, Will i ams G (eds). D i abetes, 2nd ed, Blackwell Sci ence, Vi ctoria, 1997;1:17.10-1.

Thank you for copying data from http://www.arastirmax.com